Richard Ernest Chaisson, M.D.

Headshot of Richard Ernest Chaisson
  • Director, Center for Tuberculosis Research
  • Professor of Medicine


HIV/AIDS, Infectious Disease

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital

Appointment Phone: 410-955-1725
600 N. Wolfe Street
Carnegie 3
Baltimore, MD 21287
Phone: 410-955-1755 | Fax: 410-955-0740
The Johns Hopkins Hospital - Google Maps


Dr. Richard E. Chaisson is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in epidemiology and in international health, both in the Johns Hopkins Bloomberg School of Public Health. His area of clinical expertise is infectious diseases, particularly tuberculosis and HIV/AIDS. 

Dr. Chaisson serves as the director of the Johns Hopkins University Center for Tuberculosis Research, and is the director of the Johns Hopkins Center for AIDS Research.

He received his B.S. and M.D. degrees from the University of Massachusetts. He was an intern, resident, fellow and assistant professor of medicine at the University of California, San Francisco, prior to moving to Johns Hopkins.

From 1988 to 1998 he was director of the Johns Hopkins AIDS Service, leading the inpatient Polk Service on Osler 8, a subacute care unit at Bayview Medical Center, and the outpatient Moore Clinic.  His cohort studies of HIV and with his colleague Richard Moore made major contributions to understanding the treatment and outcomes of HIV disease. In 1991 he was appointed Medical Director of the Baltimore City Health Department Tuberculosis Clinic, establishing it as a leading program in TB control. He founded the Center for TB Research in 1998, which is one of the world's leading academic center for basic, clinical, applied, and epidemiologic investigations in TB and its control.

Dr. Chaisson has conducted multiple trials of treatments and strategies to treat, prevent, and control TB, TB/HIV co-infection, and HIV.  From 2002-2014 he led the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), and from 2011-2018 he was inaugural chair of the TB Transformative Science Group of the AIDS Clinical Trials Group. In 2022 he was awarded a $200 million cooperative agreement from USAID for SMART4TB, an international research consortium to study tools to end TB globally, working with partners from multiple institutions to implement research, strengthen local capacity, and drive policy change. 

Dr. Chaisson has been recognized with numerous honors, including the HIV/AIDS Warrior Award from AIDS Action Baltimore in 2022, a Lifetime Achievement Award from the International Union Against TB and Lung Disease North American Region in 2021, election to the Association of American Professors in 2016, the Champions of TB Control Award from the U.S. Agency for International Development (USAID) in 2014 and the American Thoracic Society's World Lung Health Award in 2006. more


  • Director, Center for Tuberculosis Research
  • Director and Principal Investigator, Center for AIDS Research
  • Professor of Medicine

Departments / Divisions

Centers & Institutes



  • MD; Univ of Massachusetts Medical School-Nursing (1982)


  • Internal Medicine; University of California San Francisco School of Medicine (1985)


  • University of California San Francisco School of Medicine (1987)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (1985)

Research & Publications

Research Summary

Dr. Chaisson’s research focuses on tuberculosis and HIV infection, including global control, prevention, clinical trials and public health interventions. He leads research projects in multiple countries.

He serves as the principal investigator of numerous research grants and of the SMART4TB Consortium.

Clinical Trial Keywords

Tuberculosis; Tuberculosis screening; HIV-infected pregnant women; HIV-infected Malawians; HIV-associated lung infections and complications

Selected Publications

View all on PubMed

Dorjee K, Topgyal S, Tsewang T, Tsundue T, Namdon T, Bonomo E, Kensler C, Lhadon D, Choetso T, Nangsel T, Dolkar T, Tsekyi T, Dorjee C, Phunkyi D, Sadutshang TD, Paster Z, Chaisson RE. Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment. PLoS Med. 2021PLoS Med 18(1):e1003502.

Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Wiener M, Swindells S, Chaisson RE, for the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis.  N Engl J Med. 2021, 384:1705-18. PMCID: PMC8282329.

Swindells S, Ramchandani aakR, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L , Andersen J, Fletcher CV, Nuermberger E, Chaisson RE, for the  ACTG A5279/BRIEF TB Study Team. One Month of Rifapentine and Isoniazid to Prevent HIV-related Tuberculosis. N Engl J Med, 2019;380:1001-11. PMCID: PMC6563914.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection.  N Engl J Med. 2011;365:2155-66. PMID: 22150035.

Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE.  New regimens to prevent tuberculosis in adults with HIV infection.  N Engl J Med 2011;365:11-20. PMCID: PMC3407678.

Academic Affiliations & Courses

Courses and Syllabi

  • Epidemiologic Basis for Tuberculosis Control (340.612.01)
    Department of Epidemiology
  • Epidemiologic Basis for Tuberculosis Control (340.612.81)
    Department of Epidemiology

Activities & Honors


  • Champions of TB Control Award, U.S. Agency for International Development (USAID), 2014
  • Charles C. Shepard Science Award, Centers for Disease Control and Prevention, 2012
  • Dr. David Glasser Memorial Tuberculosis Control and Prevention Award, Maryland Department of Health and Mental Hygiene, 2008
  • World Lung Health Award, American Thoracic Society, 2006
  • HIV/AIDS Warrior Award, AIDS Action Baltimore, 2022
Is this you? Edit Profile
back to top button